SRZN
HEALTHCARESurrozen Inc
Live · NASDAQ · May 9, Close
What's Moving SRZN Today?
No stock-specific AI insight has been generated for SRZN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$34.13
Fundamentals
Trading
SRZN News
16 articles- Surrozen Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 28, 2026
- Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?Yahoo Finance·Apr 15, 2026
- Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?Yahoo Finance·Apr 14, 2026
- Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 23, 2026
- Surrozen to Present at Upcoming Healthcare Investor ConferenceYahoo Finance·Feb 25, 2026
- Surrozen Conference: CEO Details Wnt-Fzd4 Eye Disease Bet, 2026 IND Plans for SZN-8141Marketbeat·Feb 15, 2026
- We're Hopeful That Surrozen (NASDAQ:SRZN) Will Use Its Cash WiselyYahoo Finance·Dec 8, 2025
- Surrozen to Present at Upcoming Healthcare Investor ConferencesYahoo Finance·Nov 25, 2025
- Surrozen Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 7, 2025
- Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Sep 4, 2025
- Institutions own 32% of Surrozen, Inc. (NASDAQ:SRZN) shares but private equity firms control 32% of the companyYahoo Finance·Aug 30, 2025
- Surrozen Reports Second Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Aug 8, 2025
- We Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business GrowthYahoo Finance·Jul 1, 2025
- Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt PathwayYahoo Finance·May 14, 2025
- Surrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·May 9, 2025
All 16 articles loaded
Price Data
52-Week Range
$34.13
Fundamentals
Trading
About Surrozen Inc
Surrozen Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address severe diseases, leveraging its proprietary SIRPa-IgG platform for targeted immune response modulation. The company's robust pipeline includes groundbreaking antibody therapeutics primarily aimed at oncology and autoimmune disorders, reflecting its commitment to fulfilling significant unmet medical needs. Bolstered by strategic partnerships and a strong emphasis on research and development, Surrozen is strategically positioned to advance transformative therapies, marking it as a promising player within the biopharmaceutical landscape with substantial growth potential.